Toronto, Ontario — November 4, 2025 — Leads & Copy — PharmaJet, a company focused on improving injectable performance with needle-free injection technology, will present at the American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting from November 9-13 in Toronto.
Senior Vice President of Global Business Development Paul LaBarre will present on intradermal delivery of fractional-dose inactivated poliomyelitis vaccine, the impact of needle-free intradermal delivery of inactivated polio vaccine in Nigeria’s routine immunization program, and non-invasive vaccine delivery practices for latent tuberculosis infection screening.
PharmaJet’s needle-free systems have been validated with over 12 million injections, with partners discovering immunological benefits of intradermal delivery and developing new strategies to optimize candidate products using Tropis.
The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health.
For more information about partnering with PharmaJet, please look for us at one of these presentations or go to the PharmaJet website: https://www.pharmajet.com. Contact PharmaJet here. Follow us on LinkedIn.
Paul LaBarre, Senior Vice President of Global Business Development at PharmaJet.
Source: PharmaJet
